Therapeutic potential of cyanobacterial pigment protein phycoerythrin: in silico and in vitro study of BACE1 interaction and in vivo Aβ reduction

Chaubey, Mukesh Ghanshyam; Patel, Stuti; Rastogi, Rajesh P.; Srivastava, Prabhakar Lal; Singh, Arun Kumar; Madamwar, Datta; Singh, Niraj Kumar

doi:10.1016/j.ijbiomac.2019.05.006

Cited by 32 publications

(16 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The in vitro high affinity between PE and BACE1 were further confirmed with in vivo studies with C. elegans worms, where a reduction on Aβ deposition was registered. These results confirm PE as a potential active principle for development of new drugs against AD [107].…”

Section: Cyanobacteria Potential In Alzheimer Diseasesupporting

confidence: 76%

Bridging Cyanobacteria to Neurodegenerative Diseases: A New Potential Source of Bioactive Compounds against Alzheimer’s Disease

et al. 2021

View full text Add to dashboard Cite

Neurodegenerative diseases (NDs) represent a drawback in society given the ageing population. Dementias are the most prevalent NDs, with Alzheimer’s disease (AD) representing around 70% of all cases. The current pharmaceuticals for AD are symptomatic and with no effects on the progression of the disease. Thus, research on molecules with therapeutic relevance has become a major focus for the scientific community. Cyanobacteria are a group of photosynthetic prokaryotes rich in biomolecules with confirmed activity in pathologies such as cancer, and with feasible potential in NDs such as AD. In this review, we aimed to compile the research works focused in the anti-AD potential of cyanobacteria, namely regarding the inhibition of the enzyme β-secretase (BACE1) as a fundamental enzyme in the generation of β-amyloid (Aβ), the inhibition of the enzyme acetylcholinesterase (AChE) lead to an increase in the availability of the neurotransmitter acetylcholine in the synaptic cleft and the antioxidant and anti-inflammatory effects, as phenomena associated with neurodegeneration mechanisms.

show abstract

Section: Cyanobacteria Potential In Alzheimer Diseasesupporting

confidence: 76%

Bridging Cyanobacteria to Neurodegenerative Diseases: A New Potential Source of Bioactive Compounds against Alzheimer’s Disease

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Cyanobacteria are the oldest photoautotrophs with nitrogen fixation capabilities and synthesize a large variety of metabolic compounds that exhibit biomaterial and biofertilizer production capabilities, including phycobiliproteins (PBPs), which may be an important target in biotechnology and biomedical research (Gonzalez et al 2019 ; Rastogi and Sinha 2009 ; Rastogi et al 2017 ). Cyanobacteria are well-known bacteria with an immense amount of pharmacologically active functions, such as antibiotic, anti-inflammatory, antioxidant and anti-Alzheimer's disease properties (Chaubey et al 2019 ; Sonani et al 2014 ; Singh et al 2014 ). P. ludlowii has anti-inflammatory and antioxidative functions, while Cyanophyta is the dominant phylum in the endophytic bacterial community of P. ludlowii ; therefore, the medicinal value of P. ludlowii may be associated with Cyanobacteria, and the pharmacological characteristics of Cyanobacteria may contribute to the high-quality medicinal value of P. ludlowii .…”

Section: Discussionmentioning

confidence: 99%

Analysis of endophytic and rhizosphere bacterial diversity and function in the endangered plant Paeonia ludlowii

Zhang

Hong

et al. 2020

Arch Microbiol

View full text Add to dashboard Cite

Paeonia ludlowii is indigenous to Tibet and has an important ecological and economic value in China. In Tibet, P. ludlowii has been used in folk medicine with relative success. Plant microbial endophytes play an important role in plant growth, health and ecological function. The diversity of endophytic bacteria associated with P. ludlowii remains poorly understood. In this study, the structure of the endophytic bacterial communities associated with different tissues, including fruits, flowers, leaves, stems, and roots, and rhizosphere soils was analyzed with Illumina MiSeq sequencing of bacterial 16S rDNA. A total of 426,240 sequences and 4847 operational taxonomic units (OTUs) were obtained. The OTUs abundance of roots was higher than that of other tissues; however, the OTUs abundance was similar among different deep soil samples. In the plant tissues, Cyanobacteria was the most abundant bacterial phylum, followed by Proteobacteria; however, the most abundant phyla were Proteobacteria and Acidobacteria in soil samples from three different layers. In addition, the diversity and richness of the microorganisms in the soil were very similar to those in roots but higher than those in other tissues of P. ludlowii . Predictive metagenome analysis revealed that endophytic bacteria play critical functional roles in P. ludlowii . This conclusion could facilitate the study of the ecological functions of endophytic bacteria and their interactions with P. ludlowii to analyze the reasons why this important medicinal plant is becoming endangered.

show abstract

“…In more recent work, Chaubey et al [96] tested the effect of phycoerythrin in a mutant Caenorhabitis elegans Alzheimer's disease model. Results showed that a dose of 100 µg/mL of phycoerythrin led to a significant reduction in senile plaque formation when compared to untreated nematodes.…”

Section: Phycoerythrinmentioning

confidence: 99%

Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

et al. 2019

View full text Add to dashboard Cite

Macroalgae are increasingly viewed as a source of secondary metabolites with great potential for the development of new drugs. In this development, in vitro studies are only the first step in a long process, while in vivo studies and clinical trials are the most revealing stages of the true potential and limitations that a given metabolite may have as a new drug. This literature review aims to give a critical overview of the secondary metabolites that reveal the most interesting results in these two steps. Phlorotannins show great pharmaceutical potential in in vivo models and, among the several examples, the anti-dyslipidemia activity of dieckol must be highlighted because it was more effective than lovastatin in an in vivo model. The IRLIIVLMPILMA tridecapeptide that exhibits an in vivo level of activity similar to the hypotensive clinical drug captopril should still be stressed, as well as griffithsin which showed such stunning results over a variety of animal models and which will probably move onto clinical trials soon. Regarding clinical trials, studies with pure algal metabolites are scarce, limited to those carried out with kahalalide F and fucoxanthin. The majority of clinical trials currently aim to ascertain the effect of algae consumption, as extracts or fractions, on obesity and diabetes.Studies focusing on the preparation of macroalgae extracts and their chemical characterization revealed a large range of seaweed compounds with very interesting biological activities including antitumor, anti-inflammatory, antimicrobial, antidiabetic, antivirus, antihypertensive, fat-lowering, and neuroprotective activities [12][13][14][15].The large volume of studies proving the seaweed compound activities in in vitro systems [16][17][18][19] hints the need for further advancements in the knowledge about macroalgae compound efficiency in living systems (in vivo) and their use in the development of pharmaceuticals. In vitro studies are very relevant and yield very important information, but they only represent the first step of a long process, and the results obtained rarely reveal anything about the effects of a compound in vivo, because the responses observed in vitro can be magnified, diminished, or totally different in a more complex and integrated system. In fact, in vivo studies and clinical trials are those which contribute most to truly understanding the real potential of compounds as future pharmaceuticals.In this regard, the present work intends to present insight into the results obtained in the last few years regarding secondary metabolites, such as phlorotannins, halogenated compounds, fucoxanthin, and fucosterol isolated from macroalgae, involved in in vivo studies and clinical trials, identifying the research opportunities and knowledge gaps, to valorize these compounds and their natural resources. The intention is not to present an exhaustive survey of all published works, but rather a selection of authors based on the following criteria: in-depth studies involving pure compounds most characteristic f...

show abstract

Therapeutic potential of cyanobacterial pigment protein phycoerythrin: in silico and in vitro study of BACE1 interaction and in vivo Aβ reduction

Cited by 32 publications

References 48 publications

Bridging Cyanobacteria to Neurodegenerative Diseases: A New Potential Source of Bioactive Compounds against Alzheimer’s Disease

Bridging Cyanobacteria to Neurodegenerative Diseases: A New Potential Source of Bioactive Compounds against Alzheimer’s Disease

Analysis of endophytic and rhizosphere bacterial diversity and function in the endangered plant Paeonia ludlowii

Seaweed Secondary Metabolites with Beneficial Health Effects: An Overview of Successes in In Vivo Studies and Clinical Trials

Contact Info

Product

Resources

About